Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

EFESO: Study on Juvenile Onset Eosinophilic Fasciitis

International Multicentre Cohort Study on Clinical Manifestations and Response to Therapy in Juvenile Onset Eosinophilic Fasciitis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Eosinophilic fasciitis is a connective tissue disorder characterized by inflammation of the muscle fasciae, which is very rare in children. In juvenile-onset eosinophilic fasciitis (JEF), there may be severe joint involvement and skin manifestations may be less prevalent than in adults. It represents an important differential diagnosis of both juvenile-onset systemic sclerosis and localized scleroderma, and the correct classification of these patients is necessary to define a targeted diagnostic-therapeutic pathway. The diagnostic criteria proposed for eosinophilic fasciitis in the adult population do not necessarily require confirmation by skin biopsy, currently the "gold standard," which is an invasive procedure for pediatric patients; however, these criteria have never been directly applied to the pediatric population. From a therapeutic point of view, the combination of glucocorticoids and methotrexate is recommended for both adults and pediatric patients, but the data supporting this treatment in children are very limited, and there are no studies comparing the therapeutic approaches currently in use in pediatrics. Finally, there are no studies in the literature documenting the long-term prognosis of these patients in terms of functional limitations, quality of life, or complications related to the disease or treatments.

Who May Be Eligible (Plain English)

Inclusion criterai: All patients diagnosed from 2000 to 31/12/2026 - minimum follow-up 6 months - Age \<18 years at diagnosis; - All patients whose willing to sign a consent form is collected in accordance with current local legislation will also be considered enrollable. Who Should NOT Join This Trial: - Age ≥18 years at diagnosis; - Unwilling to participate into the study; - A follow-up period \< 6 months. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion criterai: All patients diagnosed from 2000 to 31/12/2026 * minimum follow-up 6 months * Age \<18 years at diagnosis; * All patients whose informed consent is collected in accordance with current local legislation will also be considered enrollable. Exclusion Criteria: * Age ≥18 years at diagnosis; * Unwilling to participate into the study; * A follow-up period \< 6 months.

Locations (15)

University of Alabama at Birmingham
Birmingham, Alabama, United States
SUNY Upstate Pediatric Rheumatology
Syracuse, New York, United States
Children's Hospital Zagreb
Zagreb, Croatia
Hamburger Zentrum für Kinder- und Jugendrheumatologie -
Hamburg, Germany
Ruth Rappaport Children's Hospital of Haifa
Haifa, Israel
Meyer Children's Hospital IRCCS
Florence, FI, Italy
IRCCS Giannina Gaslini,
Genova, Italy
Università di Udine
Udine, Italy
Iuliu Hatieganu University of Medicine and Pharmacy
Cluj-Napoca, Romania
University Children's Hospital
Ljubljana, Slovenia
Hospital Sant Joan de Déu,
Barcelona, Spain
Astrid Lindgren Children's Hospital
Solna, Stockholm County, Sweden
Cerrahpasa Medical School, Istanbul University
Istanbul, Turkey (Türkiye)
Alder Hey Children's Hospital
Liverpool, United Kingdom
Great North Children's Hospital, Newcastle Upon Tyne
Newcastle upon Tyne, United Kingdom